American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S310-S327 , December 2008

The clinical content of preconception care: women with chronic medical conditions

  • Anne L. Dunlop, MD, MPH

      Affiliations

    • Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA
    • Corresponding Author InformationReprints: Anne Dunlop MD, MPH, Department of Family and Preventive Medicine, Emory University School of Medicine, 1256 Briarcliff Road, Building A, Suite 238, Atlanta, GA 30322
    • ,
  • Brian W. Jack, MD

      Affiliations

    • Department of Family Medicine, Boston University Medical Center, Boston, MA
    • ,
  • Joseph N. Bottalico, DO

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine, Stratford, NJ
    • ,
  • Michael C. Lu, MD, MS, MPH

      Affiliations

    • Department of Obstetrics and Gynecology and Community Health Sciences, University of California, Los Angeles, Schools of Public Medicine and Public Health, Los Angeles, CA
    • ,
  • Andra James, MD, MPH

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC
    • ,
  • Cynthia S. Shellhaas, MD, MPH

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH
    • Bureau of Child and Family Health Services, State of Ohio, Columbus, OH
    • ,
  • Lynne Haygood-Kane Hallstrom, DO, CNM, MS

      Affiliations

    • Department of Obstetrics and Gynecology, Tulane University, New Orleans, LA
    • ,
  • Benjamin D. Solomon, MD

      Affiliations

    • National Human Genome Project Research Institute, National Institutes of Health, Bethesda, MD
    • ,
  • W. Gregory Feero, MD, PhD

      Affiliations

    • National Human Genome Project Research Institute, National Institutes of Health, Bethesda, MD
    • ,
  • M. Kathryn Menard, MD, MPH

      Affiliations

    • Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Mona R. Prasad, DO, MPH

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH

Received 17 June 2008 ,Accepted 8 August 2008.

References 

  1. US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau. Women's Health USA 2002. Rockville, MD: US Department of Health and Human Services; 2002;
  2. Centers for Disease Control and Prevention. Recommendations to improve preconception health and health care—United States: a report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Morb Mortal Wkly Rep. 2006;55:1–23
  3. Moos M. Preconceptional health promotion: opportunities abound. Matern Child Health J. 2002;6:71–73
  4. Weisman C. Changing definitions of women's health: implications for health care and policy. Matern Child Health J. 1997;1:179–189
  5. Clancy C, Massion C. American women's healthcare: a patchwork quilt with gaps. JAMA. 1992;268:1918–1920
  6. Allaire A, Cefalo R. Preconceptional health care model. Obstet Gynecol Reprod Biol. 1998;78:163–168
  7. Frey K. Preconception care by the non-obstetrical provider. Mayo Clin Proc. 2002;77:469–473
  8. National Center for Health Statistics. Ambulatory health care data: NAMCS description. Washington, DC: US Department of Health and Human Services, Centers for Disease and Control and Prevention, National Center for Health Statistics; 2004;Available from: http://www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm. Accessed February 2, 2008
  9. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol. 2005;105:675–685
  10. American Diabetes Association. Position statement, gestational diabetes mellitus. Diabetes care. Vol. 27, Suppl I, January 2004.
  11. Kim C, Berger DK, Chamany S. Recurrence of gestational diabetes mellitus: a systematic review. Diabetes Care. 2007;30:1314–1319
  12. Bottalico JN. Recurrent gestational diabetes: risk factors, diagnosis, management, and implications. Semin Perinatol. 2007;31:176–184
  13. Verma A, Boney C, Tucker R, Vohn BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab. 2002;87:3227–3235
  14. Kousta E, Lawrence NJ, Godsla IF, et al. Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin Endocrinol. 2003;59:289–297
  15. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes is 3-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90:4004–4010
  16. Peters RK, Kjos SL, Xiang A, Buchanan TA. Long term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. Lancet. 1996;347:227–230
  17. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States—no change since 2003-2004. NCHS data brief no 1. Hyattsville, MD: National Center for Health Statistics; 2007;Available from: http://www.cdc.gov/nchs/data/databriefs/db01.pdf. Accessed March 15, 2008
  18. Kimm S, Glynn NW, Kriska AM, et al. Decline in physical activity in black girls and white girls during adolescence. N Engl J Med. 2002;347:709
  19. Reece EA. Obesity, diabetes, and links to congenital defects: a review of the evidence and recommendations for intervention. J. Matern Fetal Neonatal Med. 2008;21:173–180
  20. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE. Preconception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996;19:514–541
  21. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. Obstet Gynecol. 1994;84:515–520
  22. Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988;319:1617–1623
  23. Taysi K. Preconceptional counseling. Obstet Gynecol Clin North Am. 1988;15:167–178
  24. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes mellitus and infant malformations. Obstet Gynecol. 2002;100:925–930
  25. Russell M, Phipps M, Olson C, Welch HG, Carpenter MW. Rates of postpartum glucose testing after gestational diabetes mellitus. Obstet Gynecol. 2006;8:1456–1462
  26. Standards of Medical Care in Diabetes—2008. Diabetes Care. 2008;31(Suppl 1):S12–S54
  27. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA. 1991;265:731–736
  28. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  29. Buchanan T, Xiang A, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  30. Gerstein H, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–1105
  31. Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22:1774–1777
  32. Elixhauser A, Weschler JM, Kitzmiller JL. Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care. 1993;16:1146–1157
  33. American Diabetes Association. Preconception care of women with diabetes. Diabetes Care. 2004;27:S76–S78
  34. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: World Health Organization; 2004;Available at: http://www.whoint/reproductive-health/publications/mec/mec.pdf. Accessed March 25, 2008
  35. ParaGard T380A Intrauterine Copper Contraceptive [prescribing information]. North Tonawanda, NY: FEI Products, LLC; 2005;Available at: http://www.paragard.com/paragard/custom_images/Prescribinginfo.pdf. Accessed March 26, 2008
  36. American Association of Clinical Endocrinologists, AACE Thyroid Task Force. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457–469
  37. Mestman JH. Hyperthyroidism in pregnancy. Clin Obstet. 1997;40:45–64
  38. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists: thyroid disease in pregnancy. Obstet Gynecol. 2002;100:387–396
  39. Klein RZ, Haddow JE, Faix JD, et al. Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol. 1991;35:41–46
  40. Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen. 2000;7:127–130
  41. Woeber KA. Subclinical thyroid dysfunction. Arch Intern Med. 1997;157:1065–1068
  42. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526–534
  43. Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. Obstet Gynecol. 1988;72:108–112
  44. Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993;81:349–353
  45. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105:239–245
  46. Pop VJ, Kujpen JL, van Baar AL, Verkerk G, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf). 1999;50:149–155
  47. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder J. Maternal hypothyroxinemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clin Endocrinol (Oxf). 2003;59:282–288
  48. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549–555
  49. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808–812
  50. Tan TO, Cheng YW, Caughey AB. Are women who are treated for hypothyroidism at risk for pregnancy complications?. Am J Obstet Gynecol. 2006;194:e1–e3
  51. Loriaux DL, Wild RA. Contraceptive choices for women with endocrine complications. Am J Obstet Gynecol. 1993;168(Suppl 6):2021–2026
  52. Goldsmith R, Sturgis S, Lerman Y, Stanbury JB. The menstrual pattern in thyroid disease. J Clin Endocrinol Metab. 1952;12:846–855
  53. Mestman JH, Godwin TM, Montoro MM. Thyroid disorders of pregnancy. Endocrinol Metab Clin North Am. 1995;24:41–71
  54. National Institutes of Health. Phenylketonuria: screening and management. NIH Consensus Statement. 2000;17:1–27
  55. Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics. 2003;112:1523–1529
  56. Rouse B, Azen C. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr. 2004;144:235–239
  57. Levy HL, Waisbren SE, Guttler F, et al. Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics. 2003;112:1548–1552
  58. Walter JH, White FJ, Hall SK, et al. How practical are recommendations for dietary control in phenylketonuria?. Lancet. 2002;360:55–57
  59. American College of Obstetricians and Gynecologists Committee on Genetics. Maternal phenylketonuria. Int J Gynecol Obstet. 2001;72:83–84
  60. Drogari E, Smith I, Beasley M, Lloyed JK. Timing of strict diet in relation to fetal damage in maternal phenylketonuria. Lancet. 1987;2:927–930
  61. Platt LD, Koch R, Azen C, et al. Maternal phenylketonuria collaborative study, obstetric aspects and outcome: the first 6 years. Am J Obstet Gynecol. 1992;166:1150–1162
  62. Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop. Epilepsy Res. 2003;52:147–187
  63. American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:944–948
  64. Cantrell DC, Riela SJ, Ramus R, Riela AR. Epilepsy and pregnancy: a study of seizure frequency and patient demographics (Abstract). Epilepsia. 1997;38:231
  65. Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. ACOG educational bulletin: seizure disorders in pregnancy. Int J Gynaecol Obstet. 1997;56:279–286
  66. Morrell MJ. Guidelines for the care of women with epilepsy. Neurology. 1998;51(Suppl 4):S21–S27
  67. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology. 1992;42(Suppl 5):119–125
  68. Koch S, Loesche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology. 1992;42(Suppl 5):83–88
  69. Stern JM. Overview of treatment guidelines for epilepsy. Curr Treat Options Neurol. 2006;8:280–288
  70. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomized study of antiepileptic drug withdrawal in patients in remission. Lancet. 1991;337:1175–1180
  71. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception. 1986;33:559–565
  72. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. Vital Health Stat 13. 2006;1–66
  73. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22
  74. Agency for Healthcare Research and Quality. Management of chronic hypertension during pregnancy. Evidence Report/Technology Assessment no.14. AHRQ publication no. 00-E011. Rockville, MD: Agency for Healthcare Research and Quality; 2000;
  75. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol. 2000;96:849–860
  76. Brown MA, Buddle ML. Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features. Med J Aust. 1996;165:360–365
  77. McCowan LM, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol. 1996;103:123–129
  78. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Obstet Gynecol. 1983;61:571–576
  79. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol. 1986;67:517–522
  80. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  81. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960–966
  82. Cunningham FG, MacDonald PC, Gant NF, et al. Endocrine disorders. In:  Cunningham FG,  Whitridge Williams J editor. Williams obstetrics. 20th ed.. Stamford, CT: Appleton & Lange; 1997;p. 1223–1238
  83. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy (Gruppo di Studio Ipertensione in Gravidanza). Br J Obstet Gynaecol. 1998;105:718–722
  84. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;1:CD002252
  85. Magee LA, Duley L. Oral beta blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;1:CD002863
  86. Magee LA, Eltran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Redprod Biol. 2000;88:15–26
  87. Management of chronic hypertension during pregnancy. Evidence report/technology assessment, number 14. Agency for Healthcare Research and Quality publication number 00-E010, August 2000. Rockville, MD: Agency for Healthcare Research and Quality; 2000;Available at: www.ahrq.gov/clinic/epcsums/pregsum.htm. Accessed May 5, 2004
  88. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318:1332–1336
  89. Duley L. Childbirth and pregnancy—pre-eclampsia and hypertension. Clin Evid [online], Issue 9, August 2003. London (United Kingdom): BMJ Publishing Group; 2003;Available at: http://clinicalevidence.bmj.com/ceweb/index.jsp. Accessed Aug. 29, 2003
  90. Gilstrap LC, Ramin SM. ACOG practice bulletin no. 29: chronic hypertension in pregnancy. Obstet Gynecol. 2001;98:177–185
  91. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program: Working Group Report on High Blood Pressure in Pregnancy. Bethesda (MD): National Heart, Lung, and Blood Institute; 2000;Available at: http://www.nhlbi.nih.gov/guidelines/archives/hbp_preg/hbp_preg_archive.pdf. Accessed May 5, 2004
  92. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of Canadian Hypertension Society Consensus Conference: 3 (Pharmacologic treatment of hypertensive disorders in pregnancy). CMAJ. 1997;157:1245–1254
  93. Neinstein L. Contraception in women with special medical needs. Comp Ther. 1998;24:229–250
  94. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women (Incidence rates in group health cooperative. Seattle, Washington, 1987-1989). Arthritis Rheum. 1991;34:1502–1507
  95. Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol. 1992;11:189–194
  96. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993;329:466
  97. Siamopoulou-Mavridou A, Manoussakis MN, Mavridis AK, Moutsopoulos HM. Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset. Ann Rheum Dis. 1988;47:982–987
  98. Ostensen M, Forger F, Villiger PM. Cytokines and pregnancy in rheumatic disease. Ann N Y Acad Sci. 2006;1069:353–363
  99. Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1983;26:1155–1159
  100. Tandon VR, Sharma S, Mahajan A, Khajuria V, Kumar A. Pregnancy and rheumatoid arthritis. Indian J Med Sci. 2006;60:334–344
  101. Nelson JL, Koepsell TD, Dugowson CE, Voigt LF, Daling JR, Hansen JA. Fecundity before disease onset in women with rheumatoid arthritis. Arthritis Rheum. 1993;36:7–14
  102. Nelson JL, Voigt LF, Koepsell TD, Dugowson CE, Daling JR. Pregnancy outcome in women with rheumatoid arthritis before disease onset. J Rheumatol. 1992;19:18–21
  103. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rhem Dis Clin North Am. 1997;23:195–212
  104. Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol. 2001;28:355–359
  105. Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976-. 1977;27:922–927
  106. Ostensen M, Forger F, Nelson JL. Pregnancy in patients with rheumatic disease inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis. 2005;64:839–844
  107. Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000;43:1010–1015
  108. Chamber CE, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8:215
  109. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum. 2005;35:112–121
  110. Hemandez-Avila M, Liang MH, Willett WC, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthrtis Rheum. 1990;33:947–953
  111. Khamashata MA, Hughes GRV. Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol. 1996;8:424–429
  112. Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001;77:157–165
  113. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum. 1997;40:1725
  114. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318–1323
  115. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;35:402–407
  116. Zemlickis D, Lishner M, Erlich R, Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen. 1993;13:139–143
  117. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 1995;38:1722–1732
  118. Armenti VT, Ahlswede KM, Ahlswede BA, Cater JR, Moritz MJ, Burke JF. National Transplantation Pregnancy Registry: analysis of outcome/risks of 394 pregnancies in kidney transplant recipients. Transplant Proc. 1994;26:2535
  119. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA. Pregnancy outcomes in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol. 1993;20:1152–1157
  120. Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BA, Moritz MJ, Burke JF. National Transplantation Pregnancy Registry—outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation. 1994;57:502–506
  121. Shaheen FAM, Al-Sulaiman MH, Al-Khader AA. Long-term nephrotoxicity after exposure to cyclosporine in utero. Transplantation. 1993;56:224–225
  122. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994;20:243–263
  123. Parke AL, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol. 1996;23:1715–1718
  124. Parke AL, Rothfield NF. Antimalarial drugs in pregnancy—the North American experience. Lupus. 1996;5(Suppl):S67–S69
  125. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis. 1996;55:486–488
  126. Houser MT, Fish AJ, Tagatz GE, Williams PP, Michael AF. Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol. 1980;138:409–413
  127. Hayslett JP, Lynn RI. Effect of pregnancy in patients with lupus nephropathy. Kidney Int. 1980;18:207–220
  128. Jungers P, Dougados M, Pelissier C, et al. Lupus nephropathy and pregnancy (Report of 104 cases in 36 patients). Arch Intern Med. 1982;142:771–776
  129. Bobrie G, Liote F, Houillier P, Grunfeld JP, Jungers P. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis. 1987;9:339–343
  130. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus. 1998;7:622–629
  131. Chapel TA, Burns RE. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol. 1971;110:366–369
  132. Primstone BL. Systemic erythematosus exacerbated by oral contraceptives. S Afr J Obstet Gynecol. 1966;4:62–63
  133. Furakawa F, Tachibana T, Imamura S, Tamura T. Oral contraceptive-induced lupus erythematosus in a Japanese woman. J Dermatol. 1991;18:56–58
  134. Garovich M, Agudelo C, Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum. 1980;23:1396–1398
  135. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus. Arthritis Rheum. 1982;25:618–623
  136. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side effects and influence on the activity of SLE. Scand J Rheumatol. 1991;20:427–433
  137. Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita RG, Merrill J. Can women with systemic lupus erythematosus safely use exogenous estrogens?. J Clin Rheumatol. 1995;1:205–212
  138. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol. 1993;32:227–230
  139. Asherson RA, Harris EN, Hughes GR, Farguharson RG. Complications of oral contraceptives and antiphospholipid antibodies: reply to the letter by Bruneau et al. Arthritis Rheum. 1988;31:575–576
  140. Fischer MJ, Lehnerz SD, Hebert JR, Parikh CR. Kidney disease is an independent risk factor for adverse fetal and maternal outcomes in pregnancy. Am J Kidney Dis. 2004;43:415–423
  141. Fink JC, Shwartz , Benedetti TJ, Stehman-Breen CO. Increased risk of adverse maternal and infant outcomes among women with renal disease. Paediatr Perinat Epidemiol. 1998;12:277–287
  142. Ramin SM, Vidaeff AC, Yeomans ER, Gilstrap LC. Chronic renal disease in pregnancy. Obstet Gynecol. 2006;108:1531–1539
  143. Lindheimer MD, Katz AI. Gestation in women with kidney disease: prognosis and management. Baillieres Clin Obstet Gynaecol. 1994;8:387–404
  144. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996;335:226–232
  145. Cunningham FG, Cox SM, Harstad TW, Mason RA, Pritchard JA. Chronic renal disease and pregnancy outcome. Am J Obstet Gynecol. 1990;163:453–459
  146. Jungers P, Houllier P, Forget D, Henry-Amar M. Specific controversies concerning the natural history of renal disease in pregnancy. Am J Kidney Dis. 1991;17:116–122
  147. Abe S. An overview of pregnancy in women with underlying renal disease. Am J Kidney Dis. 1991;17:112–115
  148. Purdy LP, Hantsch CE, Molitch ME, et al. Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care. 1996;19:1067–1074
  149. Holley JL, Bernardini J, Quadri KH, Greenberg A, Laifer SA. Pregnancy outcomes in a prospective matched control study of pregnancy and renal disease. Clin Nephrol. 1996;45:77–82
  150. Epstein FH. Pregnancy and renal disease [published erratum appears in N Engl J Med 1996;335:759]. N Engl J Med. 1996;335:277–278
  151. Jungers P, Chauveau D, Choukroun G, et al. Pregnancy in women with impaired renal function. Clin Nephrol. 1997;47:281–288
  152. Settler RW, Cunningham FG. Natural history of chronic proteinuria complicating pregnancy. Am J Obstet Gynecol. 1992;167:1219–1224
  153. Burlew BS. Managing the pregnant patient with heart disease. Clin Cardiol. 1990;13:757–762
  154. Davies GAL, Herbert WNP. Heart disease in pregnancy 1: assessment and management of cardiac disease in pregnancy. J Obstet Gynaecol Can. 2007;29:331–336
  155. Koonin LM, Atrash HK, Lawson HW, Smith JC. Maternal mortality surveillance, United States, 1979-1986. MMWR Morb Mortal Wkly Rep. 1991;40:1–13
  156. Siu SC, Sermer M, Colman JM, Alvarez AN, et al. Prospective multicentre study of pregnancy outcomes in women with heart disease. Circulation. 2001;104:515–521
  157. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006;113:517–524
  158. Nora JJ, Nora AH. Maternal transmission of congenital heart diseases: new recurrence risk figures and the questions of cytoplasmic inheritance and vulnerability to teratogens. Am J Cardiol. 1987;59:459–463
  159. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68:122–140
  160. American College of Obstetricians and Gynecologists Committee on Practice Bulletins. Obstetrics: thromboembolism in pregnancy. Int J Gynaecol Obstet. 2001;75:203–212
  161. Ressel GW. American College of Obstetricians and Gynecologists practice bulletin on preventing deep venous thrombosis and pulmonary embolism. Am Fam Physician. 2001;63:2279–2280
  162. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633–1652
  163. Siu S, Colman JM. Cardiovascular problems and pregnancy: an approach to management. Cleveland Clinic J Med. 2004;71:977–985
  164. Shime J, Mocarski EJ, Hastings D, Webb GD, McLaughlin PR. Congenital heart disease in pregnancy: short and long-term implications [published erratum in Am J Obstet Gynecol 1987;156:1361]. Am J Obstet Gynecol. 1987;156:313–322
  165. Whittemore R. Congenital heart disease: its impact on pregnancy. Hosp Pract. 1983;18:65–74
  166. Bonow RO, Carabello B, de Leon AC, et al. American College of Cardiology/American Heart Association guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol. 1998;32:1486–1588
  167. Weiss BM, von Segesser LK, Alon E, Seifert B, Turina MI. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period. 1984-1996. Am J Obstet Gynecol. 1998;179:1643–1653
  168. Weiss BM, Zemp L, Seifert B, Hess O. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650–1657
  169. Sciscione AC, Callan NA. Pregnancy and contraception. Cardiol Clin. 1993;11:701–709
  170. Cunningham FG, MacDonald PC, Gant NF. Williams obstetrics. In: 18th ed.. Norwalk (CT): Appleton & Lange; 1989;p. 984
  171. Canobbio MM, Perloff JK, Rapkin AJ. Gynecologic health of females with congenital heart disease. Int J Cardiol. 2005;98:379–387
  172. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association 2006 practice guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). J Am Coll Cardiol. 2006;48:600
  173. Sibai BM, How HY, Stella CL. Thrombophilia in pregnancy: whom to screen, when to treat. OBG Management. 2007;19:50–64
  174. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti-B2 glycoprotein-I antibodies in preeclampsia. Obstet Gynecol. 2003;102:294–300
  175. Lockwood CJ. Inherited thrombophilias in pregnant patients: Detection and treatment paradigm. Obstet Gynecol. 2002;99:333–341
  176. Silver RM, Warren JE. Preconception counseling for women with thrombophilia. Clin Obstet Gynecol. 2006;49:906–919
  177. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis (The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study). Health Technol Assess. 2006;10:1–110
  178. Lin L, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol. 2005;105:182–192
  179. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a metaanalysis. Lancet. 2003;361:901–908
  180. Vossen CY, van Korlaar IM, Cushman M, Rosendall FR, Bovill EG. Sensitivity of a questionnaire for data collection on venous thrombosis. Thromb Res. 2004;114:259–263
  181. Stella CL, How HY, Sibai BM. Thrombophilia and adverse maternal-perinatal outcome: Controversies in screening and management. Am J Perinatol. 2006;23:499–506
  182. Robertson L, Wu O, Langhorne P, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study (Thrombophilia in pregnancy: a systematic review). Br J Haematol. 2006;132:171–196
  183. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. (Erratum in: N Engl J Med 1999:341:384) N Engl J Med. 1999;340:9–13
  184. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent—the Nimes Obstetricians and Haemetologists Study 5 (NOHA5). Thromb Haemost. 1999;81:891–899
  185. DiNisio M, Peters L, Middledorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2005;CD004734
  186. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol. 2004;191:412–424
  187. Barbour LA American College of Obstetricians and Gnecologists Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin (Thromboembolism in pregnancy). Int J Gynaecol Obstet. 2001;75:203–212
  188. Kwon HL, Belanger K, Bracken MB. Asthmas prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol. 2003;13:317–324
  189. Kircher S, Schatz M, Long L. Variables affecting asthma course during pregnancy. Ann Allergy Asthma Immunol. 2002;89:463–466
  190. Schatz M, Dombrowski MP, Wise R, et al. Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol. 2003;112:283–288
  191. Demissie K, Breckenridge MB, Rhodas CG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med. 1998;158:1091–1095
  192. Liu S, Wen SW, Demissie K, Marcoux S, Kramer MS. Maternal asthma and pregnancy outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2001;184:90–96
  193. Perlow JH, Montgomery D, Morgan MA, Towers CV, Porto M. Severity of asthma and perinatal outcome. Am J Obstet Gynecol. 1992;167:963–967
  194. Schatz M, Zeiger RS, Hoffman CP, et al. Perinatal outcomes in the pregnancies of asthmatic women: a prospective controlled analysis. Am J Respir Crit Care Med. 1995;141:1170–1174
  195. Jana N, Vasishta K, Saha SC, Khunnu B. Effect of bronchial asthma on the course of pregnancy, labour, and perinatal outcome. J Obstet Gynecol. 1995;21:227–232
  196. National Asthma Education and Prevention Program Expert Panel Expert Panel Report: managing asthma during pregnancy: Recommendations for pharmacologic treatment—update 2004. NIH publication 04-5246. Bethesda, MD: National Institutes of Health; 2004;
  197. Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol. 2001;25:145–152
  198. Position statement: the use of newer asthma and allergy medications during pregnancy (American College of Obstetricians and Gynecology, and the American College of Allergy, Asthma, and Immunology). Ann Allergy Asthma Immunol. 2000;84:475–480
  199. Rodriguez-Pinilla E, Martinel-Frias ML. Corticosteroids during pregnancy and oral clefts: a case control study. Teratology. 1997;56:335–340
  200. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol. 1997;100:301–306
  201. Schatz M, Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol. 2005;95:234–238
  202. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999;93:392–395
  203. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003;111:735–742

 This work was supported in part by the National Human Genome Research Institute, National Institutes of Health.

 Conflict of Interest: Anne L. Dunlop, MD, MPH; Brian W. Jack, MD; Michael C. Lu, MD, MS, MPH; Andra James, MD, MPH; Cynthia S. Shellhaas, MD, MPH; Lynne Haygood-Kane Hallstrom, DO, CNM, MS; Benjamin D. Solomon, MD; W. Gregory Feero, MD, PhD; and M. Kathryn Menard, MD, MPH have no conflict of interest including grants, honoraria, advisory board membership, or share holdings. Joseph N. Bottalico, DO, is a member of the CDC Select Panel on Preconception Care, a voluntary unpaid position in which he represents the American College of Osteopathic Ob-Gyn and the American Osteopathic Assn (no known conflict). He is also an (appointed, unpaid) volunteer member of the NJ DHSS Diabetes Advisory Council, also without conflict. With the New Jersey Chapter of the March of Dimes, he is a member of the annual conference planning committee (no known conflict) and has received one honorarium from the March of Dimes jointly with the Johnson and Johnson foundation (New Brunswick, NJ) for a grand rounds presentation on preconception care presented to the OB-Gyn Dept at UMDNJ-SOM in December 2007. He sits on the regional MCH consortium's BOD (Southern NJ Perinatal Cooperative) and chairs their Clinical/QA committee which also presents no known conflicts. Mona R. Prasad, DO, MPH is the recipient of a $25,000 service grant from the March of Dimes for the year 2008.

PII: S0002-9378(08)00933-2

doi: 10.1016/j.ajog.2008.08.031

American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S310-S327 , December 2008

Article Tools